Physician profile
Sarju S Patel
NPI 1730384876
$96,619.40
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 90% of Uveitis and Ocular Inflammatory Disease providers received nationally (typical 2025 total: $471).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,135 · 2020: $2,859 · 2021: $17K · 2022: $12K · 2023: $26K · 2024: $19K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $20K · Food and Beverage: $8,503 · Travel and Lodging: $4,087 · Honoraria: $3,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,610.68 |
| Consulting Fee | $19,970.00 |
| Food and Beverage | $8,503.27 |
| Travel and Lodging | $4,086.57 |
| Honoraria | $3,603.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32,498.60 | 2019-2025 | |
| Allergan, INC. | $17,371.70 | 2020-2021 | |
| Regeneron Pharmaceuticals, INC. | $10,167.19 | 2023-2025 | Eylea Hd, Eylea |
| Biogen, INC. | $10,013.34 | 2022-2024 | Byooviz |
| Genentech USA, INC. | $8,221.51 | 2019-2025 | Vabysmo, Lucentis, Susvimo |
| Apellis Pharmaceuticals, INC. | $5,045.49 | 2022-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $2,266.65 | 2024-2025 | Yutiq, Purified Cortrophin Gel, Iluvien |
| Alimera Sciences, INC. | $2,068.39 | 2019-2024 | Iluvien, Yutiq |
| Eyepoint US, INC. | $1,902.48 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,884.01 | 2019-2021 | |
| Astellas Pharma US INC | $825.92 | 2024-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $793.29 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $700.14 | 2019-2022 | |
| Alcon Vision LLC | $560.70 | 2021-2025 | Constellation, Hydrus Microstent |
| Mallinckrodt Hospital Products INC. | $492.85 | 2020-2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $452.17 | 2022-2024 | Xipere, Visudyne, Retisert |
| Biotissue Holdings INC. | $345.74 | 2024 | |
| Coherus Oncology, INC. | $282.00 | 2022-2023 | |
| Genentech, INC. | $199.55 | 2022-2025 | Vabysmo, Susvimo |
| Harrow Eye, LLC | $141.85 | 2025 | Iheezo |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $53.32 | 2025 | |
| Amgen INC. | $42.10 | 2024-2025 | Pavblu |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Glaxosmithkline, LLC. | $35.00 | 2019 | |
| Thea Pharma INC. | $21.86 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarju Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.